Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 5586 · Ensuring Accurate Payments to Specialty Pharmacies Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 1396r–8 Payment for covered outpatient drugs

+45 −155 of 7 shown
More for 42 U.S.C. § 1396r–8
Read § 1396r–8Only this section
7 changes the bill asks for here, 5 carried out
  1. Carried out:

    by redesignating paragraphs (2) through (4) as paragraphs (3), (4), and (6), respectively;

  2. Carried out:

    by inserting after paragraph (1) the following new paragraph:(2) Determining applicable non-retail pharmacy actual acquisition costs.— (A) In general.— The Secretary shall conduct a survey of applicable non-retail pharmacy drug prices to determine national average drug acquisition cost benchmarks. In conducting such survey, the Secretary …

  3. Not carried out:

    in subparagraph (A), by inserting , including payment rates under managed care entities or other specified entities (as such terms are defined in section 1903(m)(9)(D)), after under this title; and

    “under this title” isn't in § 1396r–8(f)(3)(A) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“under this title” not found in /us/usc/t42/s1396r–8/f/3/A
  4. Carried out:

    in subparagraph (B), by inserting and the basis for such dispensing fees before the semicolon;

  5. Carried out:

    by inserting after paragraph (4), as so redesignated, the following new paragraph:(5) Oversight.— (A) In general.— The Inspector General of the Department of Health and Human Services shall conduct periodic studies of the survey data reported under this subsection, as appropriate, including with respect to substantial variations in acquisition costs or other …

  6. Carried out:

    in paragraph (6), as so redesignated, by inserting , and $9,000,000 for fiscal year 2027 and each fiscal year thereafter, after 2010.

  7. Not carried out:

    Section 1927(k) of the Social Security Act (42 U.S.C. 1396r–8(k)) is amended by adding the following—(12) Applicable non-retail pharmacy.— (A) In general.— The term applicable non-retail pharmacy means a pharmacy that is licensed as a pharmacy by the State and that is not a retail community pharmacy, including a pharmacy that dispenses prescription medications to patients primarily through mail and specialty pharmacies. Such term does not include nursing home pharmacies, long-term care facility pharmacies, hospital pharmacies, clinics, charitable or not-for-profit pharmacies, government pharmacies, or low dispensing pharmacies (as defined by the Secretary). (B) Identification of applicable non-retail pharmacies.— (i) In general.— For purposes of subsection (f), the Secretary shall, not later than January 1, 2028, in consultation with stakeholders as appropriate, publish guidance specifying pharmacies that meet the definition of applicable non-retail pharmacies and that will be subject to the survey requirements under subsection (f)(2). (ii) Inclusion of pharmacy type indicators.— The guidance published under clause (i) shall include pharmacy type indicators to distinguish between different types of applicable non-retail pharmacies, such as pharmacies that dispense prescriptions primarily through the mail and pharmacies that dispense prescriptions that require special handling or distribution. An applicable non-retail pharmacy may be identified through multiple pharmacy type indicators. (13) Pharmacy benefit manager.— The term pharmacy benefit manager means any person or entity that, either directly or through an intermediary, acts as a price negotiator or group purchaser on behalf of a State, managed care entity (as defined in section 1903(m)(9)(D)), or other specified entity (as so defined), or manages the prescription drug benefits provided by a State, managed care entity, or other specified entity, including the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the managing of appeals or grievances related to the prescription drug benefits, contracting with pharmacies, controlling the cost of covered outpatient drugs, or the provision of services related thereto. Such term includes any person or entity acts as a price negotiator (with regard to payment amounts to pharmacies and providers for a covered outpatient drug or the net cost of the drug) or group purchaser on behalf of a State, managed care entity, or other specified entity or that carries out 1 or more of the other activities described in the preceding sentence, irrespective of whether such person or entity calls itself a pharmacy benefit manager..

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: adding the following — QCONTENT.

§ 1396r–8(f)–(g)

Start of § 1396r–8 to (f)(1)(D)(ii) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(f)(1)(D)(iii)(iii) (iii)
The contract shall be effective for a term of 2 years.The contract shall be effective for a term of 2 years.
(f)(1)(E)(E) Availability of information to States(E) Availability of information to States
Information on retail survey prices obtained under this paragraph, including applicable information on single source drugs, shall be provided to States on at least a monthly basis. The Secretary shall devise and implement a means for providing access to each State agency designated under section 1396a(a)(5) of this title with responsibility for the administration or supervision of the administration of the State plan under this subchapter of the retail survey price determined under this paragraph.Information on retail survey prices obtained under this paragraph, including applicable information on single source drugs, shall be provided to States on at least a monthly basis. The Secretary shall devise and implement a means for providing access to each State agency designated under section 1396a(a)(5) of this title with responsibility for the administration or supervision of the administration of the State plan under this subchapter of the retail survey price determined under this paragraph.
(f)(2)(2) [inserted: Determining applicable non-retail pharmacy actual acquisition costs.—]
(f)(2)(A)(A) [inserted: In general.—]
[inserted: The Secretary shall conduct a survey of applicable non-retail pharmacy drug prices to determine national average drug acquisition cost benchmarks. In conducting such survey, the Secretary may contract services for—]
(f)(2)(A)(i)(i) [inserted: ]
[inserted: the determination of survey prices, separate from the survey prices described in paragraph (1)(A)(i), of the applicable non-retail national average drug acquisition cost for covered outpatient drugs that represent a nationwide average of consumer purchase prices for such drugs, net of all discounts and rebates (to the extent any information with respect to such discounts and rebates is available) based on a monthly survey of applicable non-retail pharmacies; and]
(f)(2)(A)(ii)(ii) [inserted: ]
[inserted: at the discretion of the Secretary, for each type of applicable non-retail pharmacy (as identified pursuant to the type indicators established by the Secretary under subsection (k)(12)(B)(ii)), the determination of survey prices, separate from the survey prices described in paragraph (1)(A)(i) or clause (i) of this subparagraph, of the national average drug acquisition cost for such type of pharmacy for covered outpatient drugs that represent a nationwide average of consumer purchase prices for such drugs, net of all discounts and rebates (to the extent any information with respect to such discounts and rebates is available) based on a monthly survey of such pharmacies.]
(f)(2)(B)(B) [inserted: Application of requirements.—]
[inserted: Subparagraphs (C), (D), and (E) of paragraph (1) shall apply to surveys of non-retail pharmacy drug prices conducted under this paragraph in the same manner as such subparagraphs apply to surveys of retail pharmacy drug prices conducted under subparagraph (1).]
(f)(2)(C)(C) [inserted: Additional requirement.—]
[inserted: In addition to the terms and conditions identified in paragraph (1)(D), and such other terms and conditions as the Secretary shall specify, a contract with a vendor under this paragraph shall require that the vendor must differentiate, in collecting and reporting survey data, the relevant pharmacy type indicator for all cost information collected, including whether a pharmacy is owned by, operated by, or otherwise affiliated with a pharmacy benefit manager and whether a pharmacy is an applicable non-retail pharmacy, and, in the case of an applicable non-retail pharmacy, which type of applicable non-retail pharmacy (as identified pursuant to the type indicators established by the Secretary under subsection (k)(12)(B)(ii)) it is.]
(f)(2)(D)(D) [inserted: Survey reporting.—]
[inserted: In order to meet the requirement of section 1902(a)(54), a State shall require that any applicable non-retail pharmacy in the State that receives any payment, reimbursement, administrative fee, discount, or rebate related to the dispensing of covered outpatient drugs to individuals receiving benefits under this title, regardless of whether such payment, reimbursement, administrative fee, discount, or rebate is received from the State or a managed care entity or other specified entity (as such terms are defined in section 1903(m)(9)(D)) directly or from a pharmacy benefit manager or another entity that has a contract with the State or a managed care entity or other specified entity (as so defined), shall respond to surveys conducted under this paragraph.]
(f)(2)(E)(E) [inserted: Survey information.—]
[inserted: Information on national drug acquisition prices obtained under this paragraph shall be made publicly available and shall include at least the following:]
(f)(2)(E)(i)(i) [inserted: ]
[inserted: The monthly response rate to the survey including a list of applicable non-retail pharmacies not in compliance with subparagraph (D).]
(f)(2)(E)(ii)(ii) [inserted: ]
[inserted: The sampling methodology and number of applicable non-retail pharmacies sampled monthly.]
(f)(2)(E)(iii)(iii) [inserted: ]
[inserted: Information on price concessions to applicable non-retail pharmacies, including discounts, rebates, and other price concessions, to the extent that such information may be publicly released and has been collected by the Secretary as part of the survey.]
(f)(2)(F)(F) [inserted: Penalties.—]
[inserted: The Secretary, in consultation with the Office of the Inspector General of the Department of Health and Human Services, shall enforce the provisions of this paragraph with respect to an applicable non-retail pharmacy through the establishment of appropriate civil monetary penalties, which may be assessed with respect to each violation or survey non-response, and with respect to each non-compliant applicable non-retail pharmacy (including a pharmacy that is part of a chain), until compliance with this paragraph has been completed. The provisions of section 1128A (other than subsections (a) and (b)) shall apply to a civil money penalty under the preceding sentence in the same manner as such provisions apply to a civil money penalty or proceeding under section 1128A(a).]
(f)(2)(G)(G) [inserted: Limitation on use of applicable non-retail pharmacy pricing information.—]
[inserted: No State shall use pricing information reported by applicable non-retail pharmacies under subparagraph (A) to develop or inform reimbursement rates for retail community pharmacies.]
(f)(3)[struck: (2)] Annual State report[inserted: (3)] Annual State report
Each State shall annually report to the Secretary information on—Each State shall annually report to the Secretary information on—
(f)(3)(A)(A) (A)
the payment rates under the State plan under this subchapter for covered outpatient drugs;the payment rates under the State plan under this subchapter for covered outpatient drugs;
(f)(3)(B)(B) (B)
the dispensing fees paid under such plan for such drugs; andthe dispensing fees paid under such plan for such drugs[inserted: and the basis for such dispensing fees]; and
(f)(3)(C)(C) (C)
utilization rates for noninnovator multiple source drugs under such plan.utilization rates for noninnovator multiple source drugs under such plan.
(f)(4)[struck: (3)] Annual State performance rankings[inserted: (4)] Annual State performance rankings
(f)(4)(A)(A) Comparative analysis(A) Comparative analysis
The Secretary annually shall compare, for the 50 most widely prescribed drugs identified by the Secretary, the national retail sales price data (collected under paragraph (1)) for such drugs with data on prices under this subchapter for each such drug for each State.The Secretary annually shall compare, for the 50 most widely prescribed drugs identified by the Secretary, the national retail sales price data (collected under paragraph (1)) for such drugs with data on prices under this subchapter for each such drug for each State.
(f)(4)(B)(B) Availability of information(B) Availability of information
The Secretary shall submit to Congress and the States full information regarding the annual rankings made under subparagraph (A).The Secretary shall submit to Congress and the States full information regarding the annual rankings made under subparagraph (A).
(f)(5)(5) [inserted: Oversight.—]
(f)(5)(A)(A) [inserted: In general.—]
[inserted: The Inspector General of the Department of Health and Human Services shall conduct periodic studies of the survey data reported under this subsection, as appropriate, including with respect to substantial variations in acquisition costs or other applicable costs, as well as with respect to how internal transfer prices and related party transactions may influence the costs reported by pharmacies affiliated with pharmacy benefit managers, wholesalers, distributors, and other entities that acquire covered outpatient drugs relative to costs reported by pharmacies not affiliated with such entities. The Inspector General shall provide periodic updates to Congress on the results of such studies, as appropriate, in a manner that does not disclose trade secrets or other proprietary information.]
(f)(5)(B)(B) [inserted: Appropriation.—]
[inserted: There is appropriated to the Inspector General of the Department of Health and Human Services, out of any money in the Treasury not otherwise appropriated, $5,000,000 for fiscal year 2027, to remain available until expended, to carry out this paragraph.]
(f)(6)[struck: (4)] Appropriation[inserted: (6)] Appropriation
Out of any funds in the Treasury not otherwise appropriated, there is appropriated to the Secretary of Health and Human Services $5,000,000 for each of fiscal years 2006 through 2010 to carry out this subsection.Out of any funds in the Treasury not otherwise appropriated, there is appropriated to the Secretary of Health and Human Services $5,000,000 for each of fiscal years 2006 through 2010[inserted: ,] [inserted: and $9,000,000 for fiscal year 2027 and each fiscal year thereafter, ]to carry out this subsection.
(g)(g) Drug use review(g) Drug use review
(g)(1)(1) In general(1) In general
(g)(1)(A)(A) (A)
In order to meet the requirement of section 1396a(a)(54) of this title, a State shall provide for a drug use review program described in paragraph (2) for covered outpatient drugs in order to assure that prescriptions (i) are appropriate, (ii) are medically necessary, and (iii) are not likely to result in adverse medical results. The program shall be designed to educate physicians and pharmacists to identify and reduce the frequency of patterns of fraud, abuse, gross overuse, excessive utilization, inappropriate or medically unnecessary care, or prescribing or billing practices that indicate abuse or excessive utilization, among physicians, pharmacists, and patients, or associated with specific drugs or groups of drugs, as well as potential and actual severe adverse reactions to drugs including education on therapeutic appropriateness, overutilization and underutilization, appropriate use of generic products, therapeutic duplication, drug-disease contraindications, drug-drug interactions, incorrect drug dosage or duration of drug treatment, drug-allergy interactions, and clinical abuse/misuse.In order to meet the requirement of section 1396a(a)(54) of this title, a State shall provide for a drug use review program described in paragraph (2) for covered outpatient drugs in order to assure that prescriptions (i) are appropriate, (ii) are medically necessary, and (iii) are not likely to result in adverse medical results. The program shall be designed to educate physicians and pharmacists to identify and reduce the frequency of patterns of fraud, abuse, gross overuse, excessive utilization, inappropriate or medically unnecessary care, or prescribing or billing practices that indicate abuse or excessive utilization, among physicians, pharmacists, and patients, or associated with specific drugs or groups of drugs, as well as potential and actual severe adverse reactions to drugs including education on therapeutic appropriateness, overutilization and underutilization, appropriate use of generic products, therapeutic duplication, drug-disease contraindications, drug-drug interactions, incorrect drug dosage or duration of drug treatment, drug-allergy interactions, and clinical abuse/misuse.

Rest of § 1396r–8 unchanged

Step through the changes